卵巢癌组织ERCC1、Vimentin表达与临床病理特征及预后的关系分析

The Relationship between the Expression of ERCC1 and Vimentin and Clinicopathological Features and Prognosis in Ovarian Cancer

目的:探讨卵巢癌组织切除修复交叉互补基因(ERCC1)、波形蛋白(Vimentin)表达与临床病理特征及预后的关系。方法:选取2015年3月~2016年2月期间首都医科大学附属北京世纪坛医院收治的卵巢癌患者83例为研究对象,收集每位患者的卵巢癌组织样本、癌旁正常组织样本,采用免疫组化SP法对各组织标本中的ERCC1、Vimentin的阳性表达率、表达水平进行检测,并分析ERCC1、Vimentin表达与卵巢癌临床病理特征间的关系,并对患者进行统一的手术治疗,分析ERCC1、Vimentin阳性表达组与阴性表达组患者的预后。结果:卵巢癌组织的ERCC1、Vimentin的阳性表达率分别为54.22%(45/83)、69.88%(58/83),高于癌旁正常组织的9.64%(8/83)、20.48%(17/83),差异有统计学意义(P<0.05)。卵巢癌组织的ERCC1、Vimentin的表达水平均高于癌旁正常组织(P<0.05)。ERCC1、Vimentin的阳性表达率与卵巢癌患者的年龄、病灶直径、病理分型无关,而与卵巢癌肿瘤的临床分期、分化程度、淋巴结转移有关。ERCC1、Vimentin阳性表达组患者的无进展生存期(PFS)、总体生存期(OS)均短于ERCC1、Vimentin阴性表达组(P<0.05)。结论:ERCC1、Vimentin的表达水平与卵巢癌的分期、分化程度、淋巴结转移有关,在卵巢癌的发生发展过程中起重要作用,ERCC1、Vimentin可能作为卵巢癌患者预后评估的参考指标。

Objective: To investigate the relationship between the expression of excision and repair of cross-complementary gene(ERCC1) and vimentin(Vimentin) and clinicopathological features and prognosis of ovarian cancer. Methods: 83 patients with ovarian cancer who were admitted to Beijing Shijitan Hospital Affiliated to Capital Medical University from March 2015 to February 2016 were selected as the study subjects. The samples of ovarian cancer tissues and adjacent normal tissues to cancer were collected from each patient. The positive rates and expression levels of ERCC1 and Vimentin were detected by immunohistochemical SP method. The relationship between ERCC1, Vimentin and clinicopathological features of ovarian cancer were analyzed, and unified surgical treatment was carried out for the patients. The prognosis of patients with ERCC1, Vimentin expression group and negative expression group were analyzed. Results: The positive rates of ERCC1 and Vimentin in ovarian cancer tissues were 54.22%(45/83) and 69.88%(58/83),respectively, which were higher than those in normal tissues adjacent to ovarian cancer tissues 9.64%(8/83) and 20.48%(17/83), with significant difference between groups(P<0.05). The expression levels of ERCC1 and Vimentin in ovarian cancer tissues were higher than those in adjacent normal tissues(P<0.05). The positive expression rates of ERCC1 and Vimentin were not related to the age, focus diameter and pathological type of ovarian cancer, but they were related to the clinical stage, differentiation degree and lymph node metastasis of ovarian cancer. The progression-free survival(PFS) and overall survival(OS) of ERCC1 and Vimentin positive expression group were shorter than those of ERCC1 and Vimentin negative expression group(P<0.05). Conclusion: The expression levels of ERCC1 and Vimentin are related to the stage, differentiation and lymph node metastasis of ovarian cancer, and they play an important role in the occurrence and development of ovarian cancer. ERCC1 and Vimentin may be used as prognostic indicators for ovarian cancer patients.